Developer docs
API playgroundTry for free, no card

Search company profiles

Allegria Therapeutics

Full company profile

uuid0003awd

Namestring
Allegria Therapeutics
Legal namestring
Allegria Therapeutics
Websiteurl
allegriatx.com
Company typeenum
Private
Founded yearint
2023
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mast cell therapeutics, allergy therapeutics, inflammatory disease drugs, biotech drug development, preclinical therapeutics
Industry2 codes
1Respiratory & Allergy Pharmaceuticals
CodeHLAIAAAHPrimaryYes
2Allergy Immunotherapy Biologics (allergen extracts, desensitization)
CodeHLAAAEAIPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Therapeutics
No data
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Allegria Therapeutics is a pre-clinical Swiss biotech company developing proprietary therapeutic approaches that directly target aberrant mast cell activation to treat allergy and mast cell-mediated inflammatory diseases. The company's pipeline consists of a lead program advancing toward preclinical development and nomination of a first clinical candidate, alongside discovery-stage programs. They focus on first-in-class therapeutics addressing significant unmet medical needs where current treatments fail to adequately control symptoms.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Allegria Therapeutics is developing a unified therapeutic pipeline targeting mast cell-mediated diseases, including allergy and inflammatory conditions. The portfolio consists of a lead program advancing toward preclinical development and nomination of the company's first clinical candidate, alongside discovery-stage programs. The company focuses on proprietary therapeutic approaches that directly target mast cell activation to address significant unmet medical needs.

Product and service1 record
1Therapeutic Pipeline for Mast Cell-Mediated Diseases
CategoryCore product
Description

A unified portfolio of proprietary therapeutic approaches targeting aberrant mast cell activation to address allergy and inflammatory conditions. The pipeline includes a lead program advancing toward preclinical development and the nomination of Allegria's first clinical candidate, plus additional discovery-stage programs. Target indications include mast cell-mediated allergic and inflammatory diseases where current therapeutics inadequately control symptoms.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1MastCURe Consortium (Cube Biotech, Fraunhofer ITMP)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-17
Description

MastCURe is a research consortium comprising Allegria Therapeutics, Cube Biotech, and Fraunhofer ITMP-IA awarded €1.3M from the Eureka Eurostars program to advance innovative mast-cell directed therapies for chronic urticaria, directly targeting aberrant mast cell activation.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Evommune
TypeEmerging player
Description

Evommune is a clinical-stage immunology biotech developing therapeutics for chronic inflammatory and allergic diseases. Its pipeline focus on mast cell and immune-mediated inflammation overlaps with Allegria's therapeutic area.

2ALK-Abelló
TypeBroad incumbent
Description

ALK-Abelló is the global leader in allergy immunotherapy and led Allegria's USD 5.1M seed extension. As both an investor and the dominant commercial player in allergy therapeutics, it is a strategic incumbent and potential acquirer or commercial partner.

3Cogent Biosciences
TypeDirect peer
Description

Cogent Biosciences is developing bezuclastinib for systemic mastocytosis and other mast cell-driven diseases. As a clinical-stage biotech focused specifically on mast cell biology, Cogent is a directly comparable peer in indication, mechanism, and stage.

4Sanofi
TypeBroad incumbent
Description

Sanofi commercializes Dupixent (with Regeneron) for atopic dermatitis, asthma, and other allergic conditions. It is a broad incumbent whose dominant position in the allergy biologics market shapes Allegria's competitive and partnership landscape.

5Stallergenes Greer
TypeBroad incumbent
Description

Stallergenes Greer is a global allergen immunotherapy specialist offering SCIT and SLIT products. It is a relevant incumbent serving the same patient population (allergy sufferers) that Allegria's therapeutics would address.

6Allergy Therapeutics
TypeBroad incumbent
Description

Allergy Therapeutics is a UK-listed specialty biotech developing allergen-specific immunotherapies for allergy. It is a relevant incumbent in the broader allergy therapeutics space where Allegria operates.

7Blueprint Medicines
TypeDirect peer
Description

Blueprint Medicines developed AYVAKIT (avapritinib), an approved therapy for systemic mastocytosis and related mast cell disorders. It is the most clinically advanced company pursuing mast cell-directed therapeutics and is the closest direct comparator for Allegria's mechanistic focus.

8AB Science
TypeDirect peer
Description

AB Science is developing masitinib, a tyrosine kinase inhibitor approved for mastocytosis and studied across allergic and inflammatory indications. It represents another directly comparable mast-cell-active therapeutic developer.

9Escient Pharmaceuticals
TypeDirect peer
Description

Escient Pharmaceuticals is a clinical-stage biotech developing MRGPRX2 antagonists and other mast cell-targeted therapeutics for inflammatory diseases. It is a directly comparable peer in mast cell biology and inflammation drug development.

10Regeneron Pharmaceuticals
TypeBroad incumbent
Description

Regeneron co-develops and commercializes Dupixent with Sanofi, the leading biologic for allergic and inflammatory diseases. It is a relevant incumbent both as a competitor and as a potential acquirer of differentiated mast cell platforms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Allegria Therapeutics

Biopharmaceutical Therapeuticsallegriatx.com

Allegria Therapeutics firmographics

Firmographics
Name
Allegria Therapeutics
Legal name
Allegria Therapeutics
Website
https://allegriatx.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Allegria Therapeutics industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
akta.pro secondary industry
Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)

Keywords

  • Mast cell therapeutics
  • Allergy therapeutics
  • Inflammatory disease drugs
  • Biotech drug development
  • Preclinical therapeutics

Where Allegria Therapeutics is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Allegria Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Allegria Therapeutics product offering

Product offering

Core offering

Allegria Therapeutics is a pre-clinical Swiss biotech company developing proprietary therapeutic approaches that directly target aberrant mast cell activation to treat allergy and mast cell-mediated inflammatory diseases. The company's pipeline consists of a lead program advancing toward preclinical development and nomination of a first clinical candidate, alongside discovery-stage programs. They focus on first-in-class therapeutics addressing significant unmet medical needs where current treatments fail to adequately control symptoms.

Product overview

Allegria Therapeutics is developing a unified therapeutic pipeline targeting mast cell-mediated diseases, including allergy and inflammatory conditions. The portfolio consists of a lead program advancing toward preclinical development and nomination of the company's first clinical candidate, alongside discovery-stage programs. The company focuses on proprietary therapeutic approaches that directly target mast cell activation to address significant unmet medical needs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Therapeutic Pipeline for Mast Cell-Mediated Diseases A unified portfolio of proprietary therapeutic approaches targeting aberrant mast cell activation to address allergy and inflammatory conditions. The pipeline includes a lead program advancing toward preclinical development and the nomination of Allegria's first clinical candidate, plus additional discovery-stage programs. Target indications include mast cell-mediated allergic and inflammatory diseases where current therapeutics inadequately control symptoms.

Companies that use Allegria Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Allegria Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Allegria Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MastCURe Consortium (Cube Biotech, Fraunhofer ITMP)coreStrategic or Co-development Partner · 17 April 2026MastCURe is a research consortium comprising Allegria Therapeutics, Cube Biotech, and Fraunhofer ITMP-IA awarded €1.3M from the Eureka Eurostars program to advance innovative mast-cell directed therapies for chronic urticaria, directly targeting aberrant mast cell activation.

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Allegria Therapeutics competitors and assessment

Company assessment

Emerging players

  • Evommune: Evommune is a clinical-stage immunology biotech developing therapeutics for chronic inflammatory and allergic diseases. Its pipeline focus on mast cell and immune-mediated inflammation overlaps with Allegria's therapeutic area.

Broad incumbents

  • ALK-Abelló: ALK-Abelló is the global leader in allergy immunotherapy and led Allegria's USD 5.1M seed extension. As both an investor and the dominant commercial player in allergy therapeutics, it is a strategic incumbent and potential acquirer or commercial partner.
  • Sanofi: Sanofi commercializes Dupixent (with Regeneron) for atopic dermatitis, asthma, and other allergic conditions. It is a broad incumbent whose dominant position in the allergy biologics market shapes Allegria's competitive and partnership landscape.
  • Stallergenes Greer: Stallergenes Greer is a global allergen immunotherapy specialist offering SCIT and SLIT products. It is a relevant incumbent serving the same patient population (allergy sufferers) that Allegria's therapeutics would address.
  • Allergy Therapeutics: Allergy Therapeutics is a UK-listed specialty biotech developing allergen-specific immunotherapies for allergy. It is a relevant incumbent in the broader allergy therapeutics space where Allegria operates.
  • Regeneron Pharmaceuticals: Regeneron co-develops and commercializes Dupixent with Sanofi, the leading biologic for allergic and inflammatory diseases. It is a relevant incumbent both as a competitor and as a potential acquirer of differentiated mast cell platforms.

Direct peers

  • Cogent Biosciences: Cogent Biosciences is developing bezuclastinib for systemic mastocytosis and other mast cell-driven diseases. As a clinical-stage biotech focused specifically on mast cell biology, Cogent is a directly comparable peer in indication, mechanism, and stage.
  • Blueprint Medicines: Blueprint Medicines developed AYVAKIT (avapritinib), an approved therapy for systemic mastocytosis and related mast cell disorders. It is the most clinically advanced company pursuing mast cell-directed therapeutics and is the closest direct comparator for Allegria's mechanistic focus.
  • AB Science: AB Science is developing masitinib, a tyrosine kinase inhibitor approved for mastocytosis and studied across allergic and inflammatory indications. It represents another directly comparable mast-cell-active therapeutic developer.
  • Escient Pharmaceuticals: Escient Pharmaceuticals is a clinical-stage biotech developing MRGPRX2 antagonists and other mast cell-targeted therapeutics for inflammatory diseases. It is a directly comparable peer in mast cell biology and inflammation drug development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Allegria Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Allegria Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Allegria Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Allegria Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allegria Therapeutics

What does Allegria Therapeutics do?

Allegria Therapeutics is a pre-clinical Swiss biotech company developing proprietary therapeutic approaches that directly target aberrant mast cell activation to treat allergy and mast cell-mediated inflammatory diseases. The company's pipeline consists of a lead program advancing toward preclinical development and nomination of a first clinical candidate, alongside discovery-stage programs. They focus on first-in-class therapeutics addressing significant unmet medical needs where current treatments fail to adequately control symptoms.

Is Allegria Therapeutics a public or private company?

Allegria Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Allegria Therapeutics founded?

Allegria Therapeutics was founded in 2023. It employs 1 to 10 people.

Where is Allegria Therapeutics based?

Allegria Therapeutics is headquartered in Basel, Switzerland, in the Europe region.

Who are Allegria Therapeutics's main competitors?

Evommune is listed as an emerging player. Broad incumbents are ALK-Abelló, Sanofi, Stallergenes Greer, Allergy Therapeutics and Regeneron Pharmaceuticals. Direct peers are Cogent Biosciences, Blueprint Medicines, AB Science and Escient Pharmaceuticals.

Does Allegria Therapeutics have an API?

No public API is recorded for Allegria Therapeutics.

What industry is Allegria Therapeutics in?

Allegria Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals, with a secondary code of HLAAAEAI, Allergy Immunotherapy Biologics (allergen extracts, desensitization). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Allegria Therapeutics: $5.1 Million Seed Extension Raised To Advance Mast Cell Disease PipelineAllegria Therapeutics closed a $5.1 million seed extension financing led by ALK-Abelló to advance its mast cell disease pipeline. The funds will progress its lead program toward preclinical candidates and expand discovery-stage programs. The company aims to nominate its first clinical candidate.VenturelabAllegria Therapeutics secures USD 5.1 million Seed extension financingBasel-based Allegria Therapeutics, a Swiss biotech company focused on mast cell-mediated diseases, has closed a USD 5.1 million seed extension round. The financing was led by ALK-Abelló with participation from HighLight Capital, the Lichtsteiner Foundation, and Forty51 Ventures. The funding will support moving the company's lead program toward pre-clinical candidates and strengthen its early-stage research efforts.FinSMEsAllegria Therapeutics Raises $5.1M in Seed Extension FundingAllegria Therapeutics raised $5.1M in seed extension funding led by ALK Abelló, with participation from HighLight Capital, Lichtsteiner Foundation, and Forty51 Ventures. The company will use the funds to advance its lead program toward pre-clinical candidates and support its first clinical candidate. Dr. Peter Sejer Andersen joined the board as non-executive director.InvestorshangoutAllegria Therapeutics Raises $5.1 Million for GrowthAllegria Therapeutics, a Swiss biotech company founded in 2023, has completed a seed extension financing round raising USD 5.1 million to advance its therapeutic programs targeting mast cell-mediated diseases and allergies. The funding round was led by ALK Abelló alongside HighLight Capital, Lichtsteiner Foundation, and co-founding investor Forty51 Ventures, with Dr. Peter Sejer Andersen joining Allegria's Board. The capital will support preclinical development and strengthen research initiatives in mast cell modulation therapies.PR NewswireALLEGRIA THERAPEUTICS SECURES USD 5.1 MILLION SEED EXTENSION FINANCINGAllegria Therapeutics, a Swiss biotech company focused on mast cell-mediated diseases, has completed a USD 5.1 million seed extension financing round led by ALK Abelló with participation from HighLight Capital, Lichtsteiner Foundation, and co-founding investor Forty51 Ventures. The funds will support progression of the company's lead program toward pre-clinical and clinical candidate nominations while advancing discovery-stage programs. Dr. Peter Sejer Andersen from ALK Abelló has joined Allegria's Board as a non-executive director following this financing.startupticker.chUSD 3.5 Million to tackle allergies and inflammatory diseasesBasel-based startup Allegria Therapeutics has closed a USD 3.5 million seed financing round led by Forty51 Ventures to advance research into therapeutics for mast cell-mediated diseases. Coinciding with this funding, co-founder Dr. Maria van Dongen was appointed as the company's new CEO.PR NewswireALLEGRIA THERAPEUTICS ANNOUNCES SEED FINANCING TO ADVANCE PIPELINE OF NOVEL AND SELECTIVE THERAPEUTIC APPROACHES FOR MAST CELL-MEDIATED DISEASESAllegria Therapeutics announced a $3.5 million seed financing round led by investor Forty51 Ventures to advance its pipeline of therapeutic approaches for mast cell-mediated diseases. The company simultaneously appointed co-founder Maria van Dongen, PhD, as Chief Executive Officer. Allegria plans to utilize the funds to progress proprietary targets that selectively modulate mast cells to address allergy and inflammatory conditions.BioSpaceAllegria Therapeutics Announces Seed Financing to Advance Pipeline of Novel and Selective Therapeutic Approaches for Mast Cell-Mediated DiseasesAllegria Therapeutics announced a $3.5 million seed financing round led by investor Forty51 Ventures to advance its pipeline of therapies for mast cell-mediated diseases. Concurrently, co-founder Maria van Dongen was appointed as Chief Executive Officer, bringing extensive pharmaceutical industry experience to the role. The company plans to utilize the funding to progress proprietary therapeutic approaches targeting allergic and inflammatory conditions.FinSMEsAllegria Therapeutics Raises USD3.5M in Seed FundingAllegria Therapeutics raised USD 3.5M in Seed funding to advance its therapeutics pipeline for mast cell-mediated diseases. The funding will support the development of proprietary therapeutic approaches aimed at effectively addressing patient needs, as the company collaborates with several renowned experts in the field. Additionally, Allegria announced the appointment of co-founder Maria van Dongen, PhD, as Chief Executive Officer.